Non-operative management of spinal metastases: A prognostic model for failure.
Adult
Aged
Aged, 80 and over
Antineoplastic Agents
/ therapeutic use
Arthrodesis
Breast Neoplasms
/ pathology
Carcinoma
/ secondary
Chemoradiotherapy
Decompression, Surgical
Female
Fractures, Spontaneous
/ physiopathology
Humans
Liver Neoplasms
/ secondary
Lung Neoplasms
/ pathology
Lymphocyte Count
Lymphoma
/ therapy
Male
Middle Aged
Mortality
Multiple Myeloma
/ secondary
Platelet Count
Prognosis
Risk Factors
Spinal Cord Compression
/ physiopathology
Spinal Neoplasms
/ physiopathology
Treatment Failure
Vertebral Body
/ surgery
Ambulatory function
Non-operative treatment
Prognosis
Spinal metastases
Surgery
Survival
Journal
Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
08
06
2019
revised:
11
08
2019
accepted:
26
10
2019
pubmed:
11
11
2019
medline:
29
4
2021
entrez:
11
11
2019
Statut:
ppublish
Résumé
To describe patient-specific characteristics associated with non-operative failure leading to surgery. We conducted a retrospective review of patients treated for spinal metastases from 2005 to 2017. We deemed patients as failures if they were treated non-operatively and then received a surgical intervention within one year of starting a non-operative regimen. We used multivariable Poisson regression to identify factors associated with non-operative failure. We conducted internal validation using bootstrapping with 1000 replications. We identified 1205 patients with spinal metastases, of whom 834 were initially treated non-operatively and constituted the analytic sample. Of these 77 (9%) went on to have surgery within 1-year of presentation and were deemed non-operative treatment failures. We identified vertebral body collapse and/or pathologic fracture (adjusted Risk Ratio [RR] 1.75; 95% Confidence Interval [CI] 1.11, 2.76) and neurologic signs or symptoms at presentation (RR 1.90; 95% CI 1.19, 3.03) as factors independently associated with an increased risk of non-operative failure. Platelet-lymphocyte ratio >155, a marker for inflammatory state, was also associated with an increased risk of failure (RR 2.32; 95% CI 1.15, 4.69). Failure rates among those with 0, 1, 2 or all three of these risk factors were 5%, 7%, 12% and 20%, respectively (p = 0.004). We found that 9% of patients with spinal metastases initially treated non-operatively received surgery within 1-year of commencing care. The likelihood of surgery increased with the number of risk factors. These results can be used in counseling and shared decision making at the time of initial presentation.
Identifiants
pubmed: 31707291
pii: S0303-8467(19)30370-1
doi: 10.1016/j.clineuro.2019.105574
pmc: PMC6949394
mid: NIHMS1542421
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
105574Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR071464
Pays : United States
Organisme : NIAMS NIH HHS
ID : P30 AR072577
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
PLoS One. 2018 Jul 26;13(7):e0200936
pubmed: 30048474
Global Spine J. 2018 Sep;8(6):638-651
pubmed: 30202719
Ann Surg Oncol. 2018 Oct;25(11):3341-3349
pubmed: 30066226
Spine J. 2018 Oct;18(10):1804-1814
pubmed: 29567516
Br J Cancer. 2018 Sep;119(6):737-743
pubmed: 30116026
Spine J. 2019 Jan;19(1):144-156
pubmed: 29864546
Spine (Phila Pa 1976). 2016 Feb;41(3):E155-62
pubmed: 26866742
J Am Acad Orthop Surg. 2011 Jan;19(1):37-48
pubmed: 21205766
J Bone Joint Surg Am. 2016 Mar 2;98(5):396-402
pubmed: 26935462
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Neuro Oncol. 2014 Jul;16(7):991-8
pubmed: 24470544
PLoS One. 2017 Dec 29;12(12):e0190342
pubmed: 29287117
Cancer Treat Rev. 2018 Sep;69:29-38
pubmed: 29870874
Spine J. 2016 Apr;16(4):482-90
pubmed: 26409416
Neurosurgery. 2015 Nov;77(5):698-708; discussion 708
pubmed: 26204361
Lancet. 2005 Aug 20-26;366(9486):643-8
pubmed: 16112300
Spine J. 2018 Jun;18(6):935-940
pubmed: 29031992
J Clin Oncol. 2010 Aug 1;28(22):3597-604
pubmed: 20606090
Spine J. 2010 Aug;10(8):708-14
pubmed: 20650409
Spine (Phila Pa 1976). 2012 Jan 1;37(1):78-84
pubmed: 21629164
Spine J. 2018 Jul;18(7):1109-1115
pubmed: 29122701
Cancer. 2019 Aug 1;125(15):2631-2637
pubmed: 30985913
Orthop Traumatol Surg Res. 2018 Sep;104(5):589-595
pubmed: 30012505
J Bone Joint Surg Am. 2016 Nov 2;98(21):1767-1776
pubmed: 27807108